The Rosen Law Firm is currently evaluating potential securities claims on behalf of shareholders who purchased Disc Medicine, Inc. (NASDAQ: IRON) stock. The investigation centers on allegations that the company provided misleading business information to the public regarding its development pipeline. Investors affected by the February market correction may be eligible for compensation through a proposed class action lawsuit, which operates on a contingency fee basis.
In section Releases
Investors Scrutinize Disc Medicine Following FDA Rejection
A 22% plunge in Disc Medicine’s stock price on February 13, 2026, followed an FDA decision to deny approval for the company’s bitopertin program. The agency issued a Complete Response Letter, citing significant uncertainties in the drug application that require additional evidence to proceed, triggering an investigation by the Rosen Law Firm.
Those who held securities during the relevant period are encouraged to contact attorney Phillip Kim to discuss their legal standing. While the firm highlights its history of securities litigation and settlement recoveries, the ongoing inquiry remains in the preliminary stages. Prospective class members can submit their information through the firm’s online portal to determine if they qualify for participation in the recovery effort.
Comments (0)
No comments yet. Be the first!